BLOG/🇺🇸United States··daily

Significant Contract Modifications ($10M+) — March 24, 2026

Significant Contract Modifications ($10M+)

7 total filings analysed

Executive Summary

HHS dominates with $1.19B across four contracts (28% of total), signaling sustained federal health IT, biopharma, and R&D spending through 2027+. NASA's $2.95B Caltech JPL modification anchors 68% of volume but offers neutral equity impact as a nonprofit. Bullish signals in for-profit IT/services (Elevance, Emergent, ElbitAmerica, Pyramid) highlight $1.13B in reliable revenue ramps, with minimal outlays in newer awards indicating near-term cash flow acceleration.

Tracking the trend? Catch up on the prior Significant Contract Modifications ($10M+) digest from March 22, 2026.

Investment Signals(3)

  • HHS Health IT & Biopharma Revenue Lock-in(HIGH)

    Four HHS awards totaling $1.19B to Elevance, Emergent, RTI, and Mount Sinai provide multi-year visibility through 2027, with $694M already outlayed signaling steady execution.

  • Defense/Security Contract Ramps(MEDIUM)

    $105M DHS surveillance award to ElbitAmerica and $100M GSA IT BPA to Pyramid signal future revenue from 2026 starts, with options adding $4M+ potential.

  • Nonprofit Dominance in R&D(HIGH)

    Three nonprofits (Caltech, RTI, Mount Sinai) capture $3.21B (74% of total) in space/health R&D, limiting direct equity upside despite scale.

Risk Flags(3)

  • Execution[HIGH RISK]

    Long tenors (avg. end 2027+) across all contracts expose to funding cuts/delays, with $2.9B Caltech and $505M Elevance most extended.

  • Market[MEDIUM RISK]

    Firm fixed-price terms in Emergent ($422M) and Elbit ($105M) risk cost overruns; time-materials in Pyramid adds labor volatility.

  • Regulatory[MEDIUM RISK]

    Foreign-owned entities (Emergent Canada, ElbitAmerica) in HHS/DHS face scrutiny amid $527M obligations.

Opportunities(2)

  • $201M+ in unexercised options (e.g., Caltech $202M, Emergent $284M, Mount Sinai $44M) across five contracts offer upside through 2029.

  • Small business set-asides like Pyramid's $100M GSA BPA position for HUD/GSA IT expansion.

Sector Themes(3)

  • 60%+ non-NASA value ($1.19B) in HHS IT, biopharma, and analysis signals multi-year federal prioritization amid aging population needs.

  • $2.95B NASA JPL mod underscores FFRDC reliance for Europa/missions through 2028.

  • DHS/GSA awards ($205M) target surveillance/networks starting 2026 with extensions to 2030.

Watch List(4)

  • 👁

    {"entity"=>"Elevance Health (National Government Services)", "reason"=>"$505M CMS IT fully obligated through 2027 with $259M outlayed", "trigger"=>"Award fee realizations or subaward shifts >10%"}

  • 👁

    {"entity"=>"Emergent BioSolutions", "reason"=>"$422M VIGIV obligation +$284M options in biopharma thru 2029", "trigger"=>"Option exercises or outlay >$300M"}

  • 👁

    {"entity"=>"ElbitAmerica (Elbit Systems)", "reason"=>"$105M DHS surveillance from 2026 with foreign-ownership overlay", "trigger"=>"Initial outlays or policy reviews"}

  • 👁

    {"entity"=>"Pyramid Systems", "reason"=>"$100M small biz GSA BPA for HUD IT ending 2026", "trigger"=>"Extension to Sep 2026 or new call awards"}

Get daily alerts with 3 investment signals, 3 risk alerts, 2 opportunities and full AI analysis of all 7 filings

🇺🇸 More from United States

View all →
Significant Contract Modifications ($10M+) — March 24, 2026 | Gunpowder Blog